Catch people early, before they deteriorate.
Em meio à persistência da pandemia, o Brasil ampliou em agosto de 2021 seu arsenal terapêutico contra a COVID-19 com a aprovação unânime do sotrovimabe pela Anvisa — um anticorpo monoclonal que, ao bloquear a proteína spike do vírus, oferece às populações mais vulneráveis uma chance de evitar a deterioração antes que ela se instale. A decisão reflete o esforço contínuo da ciência em transformar conhecimento molecular em proteção humana concreta, ainda que a incerteza diante de novas variantes lembre que nenhuma ferramenta chega sem seus limites.
- Com 79% de redução no risco de progressão da doença, o sotrovimabe chega como uma resposta urgente para pacientes em situação de alto risco que ainda não precisam de oxigênio — uma janela terapêutica estreita, mas decisiva.
- A aprovação delimita com precisão quem pode se beneficiar: maiores de 12 anos com comorbidades como diabetes, obesidade ou imunossupressão, tratados em até cinco dias do início dos sintomas — qualquer atraso pode fechar essa janela.
- Uma fronteira crítica tensiona o uso do medicamento: pacientes já em suplementação de oxigênio não podem recebê-lo, pois os dados sugerem que o tratamento pode piorar o quadro nesses casos.
- A eficácia contra variantes emergentes permanece uma incógnita — estudos in vitro são encorajadores, mas o mundo real ainda não confirmou o que o laboratório promete.
- O sotrovimabe torna-se o quinto tratamento aprovado pela Anvisa desde o início da pandemia, compondo um arsenal crescente que inclui remdesivir, Regen-cov, bamlanivimabe com etesevimabe e regdanvimabe — cada um com seu perfil e suas restrições.
A Anvisa aprovou por unanimidade, em agosto de 2021, o uso emergencial do sotrovimabe, anticorpo monoclonal desenvolvido pela GlaxoSmithKline Brasil para tratar casos leves a moderados de COVID-19 em pacientes com alto risco de agravamento. O pedido havia sido submetido em julho, e a agência agiu com rapidez para autorizar o novo tratamento.
O medicamento é indicado para pessoas a partir de 12 anos e com pelo menos 40 quilogramas, portadoras de condições como obesidade, diabetes, doenças cardiovasculares, pulmonares, renais ou hepáticas crônicas, além de imunossupressão. A dose única deve ser administrada em ambiente hospitalar dentro dos primeiros cinco dias de sintomas. Há, porém, uma limitação fundamental: pacientes que já necessitam de oxigênio estão excluídos, pois as evidências indicam que o tratamento pode piorar o quadro nesses casos.
O mecanismo de ação foi explicado pela revisora do pedido: o sotrovimabe é um anticorpo de engenharia que imita a resposta imune natural, bloqueando a proteína spike do SARS-CoV-2 e impedindo que o vírus penetre nas células humanas. Os dados clínicos sustentaram a aprovação com força — uma redução de 79% no risco de progressão da doença, com impacto direto na redução de hospitalizações e mortes.
A agência reconheceu, no entanto, que a eficácia contra variantes emergentes ainda não está confirmada no mundo real, apesar de estudos laboratoriais favoráveis. Gestantes também exigem cautela, dada a escassez de dados específicos para essa população.
Com essa aprovação, o sotrovimabe passa a integrar um conjunto de cinco tratamentos autorizados pela Anvisa desde o início da pandemia, ao lado de remdesivir, Regen-cov, bamlanivimabe com etesevimabe e regdanvimabe — um arsenal em construção, cada opção moldada por suas próprias possibilidades e limites.
Brazil's health regulator gave unanimous approval on Wednesday to a new weapon against COVID-19: sotrovimabe, a monoclonal antibody treatment for patients with mild to moderate illness who face a high risk of deterioration. The pharmaceutical company GlaxoSmithKline Brasil had submitted the request in July, and Anvisa—the National Health Surveillance Agency—moved swiftly to authorize its emergency use.
The drug targets a specific population: those twelve years and older, weighing at least forty kilograms, whose cases show early warning signs. The agency identified the vulnerable groups with precision. Advanced age, obesity, cardiovascular disease including hypertension, chronic lung disease, asthma, diabetes, chronic kidney disease (including dialysis patients), chronic liver disease, and immunosuppression all qualified as risk factors that made someone eligible. The treatment must begin within five days of symptom onset and comes as a single dose, administered only in hospital settings.
One critical limitation: the drug cannot be given to patients already requiring oxygen supplementation. Clinical evidence suggested that in such cases, the treatment might actually worsen outcomes rather than improve them. This boundary mattered enormously for determining who could benefit.
Meiruze de Sousa Freitas, the official who reviewed the emergency authorization request, explained the mechanism in straightforward terms. The drug is a laboratory-engineered antibody that mimics the body's natural immune response. It targets the spike protein of SARS-CoV-2, the structure the virus uses to breach human cells. By blocking that attachment point, sotrovimabe prevents infection from taking hold in the first place.
The clinical data proved compelling. Gustavo Mendes, the agency's general manager for medications and biological products, highlighted what the trials had shown: a seventy-nine percent reduction in the risk of disease progression among treated patients. That figure translated into meaningful protection against hospitalization and death. Mendes called it a significant outcome, the kind of result that changes how doctors approach treatment decisions.
Yet uncertainty lingered. The agency acknowledged that real-world effectiveness against emerging variants remained unknown. In-vitro laboratory studies suggested the drug would hold up against new strains, but that reassurance came with caveats. Pregnant women presented another question mark—the available data was too limited to offer clear guidance, so caution would be necessary if the drug was used in that population.
Sotrovimabe became the fifth COVID-19 treatment approved by Anvisa since the pandemic began. Remdesivir had arrived first, receiving full registration in March. Regen-cov, a combination of monoclonal antibodies, followed with emergency authorization. In May, the agency approved a treatment from Eli Lilly combining two biological medications: bamlanivimab and etesevimab. Then in August came regdanvimab from Celltrion Healthcare, another option for mild to moderate cases in adults not yet requiring oxygen but at high risk of worsening. The approval of sotrovimabe added another option to a growing toolkit, each with its own profile and constraints.
Citas Notables
It is a laboratory-engineered antibody that mimics the body's natural immune response, targeting the spike protein of SARS-CoV-2 to prevent viral entry into human cells.— Meiruze de Sousa Freitas, Anvisa official
A seventy-nine percent reduction in disease progression risk represents a significant outcome with meaningful protection against hospitalization and death.— Gustavo Mendes, Anvisa general manager for medications and biological products
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that this drug works specifically for mild to moderate cases? Couldn't it help sicker patients too?
That's the paradox. The sicker you are—the moment you need oxygen—the drug appears to backfire. It's not that it stops working. It's that something about how it interacts with severely compromised lungs makes things worse. So the window where it helps is narrow and urgent: catch people early, before they deteriorate.
The 79 percent figure sounds impressive. But impressive compared to what? What happens to people who don't get the drug?
That's the baseline question nobody quite answers in the approval announcement. The seventy-nine percent is the reduction in progression risk—meaning fewer people got sicker or died. But we don't know the absolute numbers. Did it prevent one death per hundred patients, or one per ten? The percentage alone doesn't tell you.
You mentioned variants. How worried should people be that this won't work against new strains?
Worried enough to watch, but not panicked yet. The lab tests suggest it holds up. But those are controlled conditions. Real-world variants move fast and change in ways we can't always predict. The agency is being honest about the gap between what we know in the lab and what we'll see in hospitals.
Why the five-day window? Why does timing matter so much?
Because monoclonal antibodies work by blocking the virus before it multiplies out of control. Once the infection has spread deep into your lungs and your immune system is already in overdrive, introducing an antibody is like closing the barn door after the horses have scattered. The earlier you intervene, the more cells you can protect.
So this is really a drug for the worried well—people who test positive and have risk factors, not people already in crisis.
Exactly. It's preventive medicine dressed up as treatment. You're trying to stop the cascade before it starts, not reverse it once it's underway.